PH26920A - Medicaments for the treatment of cerebral apoplexy - Google Patents

Medicaments for the treatment of cerebral apoplexy Download PDF

Info

Publication number
PH26920A
PH26920A PH39203A PH39203A PH26920A PH 26920 A PH26920 A PH 26920A PH 39203 A PH39203 A PH 39203A PH 39203 A PH39203 A PH 39203A PH 26920 A PH26920 A PH 26920A
Authority
PH
Philippines
Prior art keywords
active compounds
use according
group
medicaments
treatment
Prior art date
Application number
PH39203A
Other languages
English (en)
Inventor
Joerg Traber
Gerhard-Wilheim Bielenberg
Original Assignee
Troponwerke Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Troponwerke Gmbh & Co Kg filed Critical Troponwerke Gmbh & Co Kg
Publication of PH26920A publication Critical patent/PH26920A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/45Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Hydrogenated Pyridines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Instructional Devices (AREA)
  • Cephalosporin Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
PH39203A 1988-09-20 1989-09-06 Medicaments for the treatment of cerebral apoplexy PH26920A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3831888A DE3831888A1 (de) 1988-09-20 1988-09-20 Arzneimittel zur behandlung von apoplexia cerebri

Publications (1)

Publication Number Publication Date
PH26920A true PH26920A (en) 1992-12-03

Family

ID=6363313

Family Applications (1)

Application Number Title Priority Date Filing Date
PH39203A PH26920A (en) 1988-09-20 1989-09-06 Medicaments for the treatment of cerebral apoplexy

Country Status (15)

Country Link
US (3) US4988700A (ko)
EP (1) EP0360077B1 (ko)
JP (1) JP2669507B2 (ko)
KR (2) KR0135307B1 (ko)
AT (1) ATE91623T1 (ko)
AU (1) AU619895B2 (ko)
CA (1) CA1331139C (ko)
DE (2) DE3831888A1 (ko)
DK (1) DK175128B1 (ko)
ES (1) ES2058426T3 (ko)
FI (1) FI894404A (ko)
HU (1) HU203475B (ko)
IE (1) IE62697B1 (ko)
IL (1) IL91660A (ko)
PH (1) PH26920A (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06504279A (ja) * 1990-12-24 1994-05-19 メレルダウファーマス−ティカルズ インコーポレイテッド 欝病及び躁病の治療におけるある種のグルタルイミド誘導体の用途
DE4135473A1 (de) * 1991-10-28 1993-04-29 Bayer Ag Triazaspirodecanon-methylchromane
DE4138756A1 (de) * 1991-11-26 1993-05-27 Troponwerke Gmbh & Co Kg Kombination mit neuroprotektiver wirkung
EP0663014B1 (en) * 1992-09-25 2004-08-18 Synaptic Pharmaceutical Corporation Dna encoding human alpha 1 adrenergic receptors and uses thereof
WO1994009765A1 (en) * 1992-10-23 1994-05-11 New York University Functional interactions between glial s-100b and central nervous system serotonergic neurons
ATE255888T1 (de) 1998-06-01 2003-12-15 Ortho Mcneil Pharm Inc Tetrahydronaphtalene verbindungen und deren verwendung zur behandlung von neurodegenerativen krankheiten
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
DE69919707T2 (de) 1998-06-19 2005-09-01 Chiron Corp., Emeryville Glycogen synthase kinase 3 inhibitoren
EP1100794A1 (en) 1998-07-17 2001-05-23 Synaptic Pharmaceutical Corporation COMPOUNDS SPECIFIC FOR THE HUMAN $g(a) 1d? ADRENERGIC RECEPTOR AND USES THEREOF
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
DE19900544A1 (de) * 1999-01-11 2000-07-13 Basf Ag Verwendung von Verbindungen der Formel I zur Prophylaxe und Therapie der zerebralen Ischämie
US20040106623A1 (en) * 1999-07-16 2004-06-03 Synaptic Pharmaceutical Corporation Compounds specific for the human alpha1d adrenergic receptor and uses thereof
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
US20040002500A1 (en) * 2002-06-28 2004-01-01 Fabre Kramer Pharmaceutical, Inc. Methods for treating attention deficit disorder
US20040077996A1 (en) * 2002-10-22 2004-04-22 Jasperson Keith E. Drug infusion system with multiple medications
US7375219B2 (en) * 2005-04-13 2008-05-20 Neuraxon, Inc. Substituted indole compounds having NOS inhibitory activity
TW200808780A (en) * 2006-04-13 2008-02-16 Neuraxon Inc 1,5 and 3,6- substituted indole compounds having NOS inhibitory activity
US20090131503A1 (en) * 2007-11-16 2009-05-21 Annedi Subhash C 3,5 - substituted indole compounds having nos and norepinephrine reuptake inhibitory activity
WO2009064505A1 (en) * 2007-11-16 2009-05-22 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating visceral pain
BRPI0820632A2 (pt) * 2007-11-16 2015-06-16 Neuraxon Inc Compostos de indol e métodos para tratamento de dor visceral
KR102357405B1 (ko) 2021-05-07 2022-02-09 정진구 호흡기 운동기구

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8810748D0 (en) * 1988-05-06 1988-06-08 Beecham Wuelfing Gmbh & Co Kg Novel treatment

Also Published As

Publication number Publication date
DE3831888A1 (de) 1990-03-29
ATE91623T1 (de) 1993-08-15
CA1331139C (en) 1994-08-02
HUT52699A (en) 1990-08-28
AU4145689A (en) 1990-03-29
EP0360077A2 (de) 1990-03-28
JP2669507B2 (ja) 1997-10-29
DK461689A (da) 1990-03-21
IL91660A (en) 1993-08-18
US5155128A (en) 1992-10-13
FI894404A0 (fi) 1989-09-18
IL91660A0 (ko) 1990-04-29
AU619895B2 (en) 1992-02-06
US5070102A (en) 1991-12-03
HU203475B (en) 1991-08-28
EP0360077A3 (de) 1992-03-11
ES2058426T3 (es) 1994-11-01
DK175128B1 (da) 2004-06-07
KR0146486B1 (ko) 1998-08-17
IE62697B1 (en) 1995-02-22
JPH02121935A (ja) 1990-05-09
FI894404A (fi) 1990-03-21
US4988700A (en) 1991-01-29
KR0135307B1 (ko) 1998-04-23
DE58904960D1 (de) 1993-08-26
DK461689D0 (da) 1989-09-19
IE892990L (en) 1990-03-20
KR900004352A (ko) 1990-04-12
EP0360077B1 (de) 1993-07-21

Similar Documents

Publication Publication Date Title
PH26920A (en) Medicaments for the treatment of cerebral apoplexy
KR100443850B1 (ko) 헤테로시클릭 화합물의 도파민-d3 리간드로서의 용도
JP2002523447A (ja) 5−ht6アンタゴニストの使用
CZ291596A3 (en) Novel application of serotonin antagonists
JPH11503738A (ja) 尿失禁を治療するためのα▲下1L▼アゴニストの使用
CA2378428C (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
JPS6197228A (ja) ジヒドロピリジン類とace阻害剤との配合物
US20170065608A1 (en) Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome
US6967211B2 (en) Remedial agent for chronic articular rheumatism
US6436944B1 (en) Combination effective for the treatment of impotence
CA2167004C (en) Agent for treating mental disorders associated with cerebrovascular disorders
HUT77735A (hu) Triazinszármazékok és ezeket tartalmazó gyógyászati készítmények
US5200410A (en) Medicaments for the treatment of cerebral apoplexy
JP2618449B2 (ja) アルコール中毒治療用薬剤
CA2436083A1 (en) Use of dual h3/m2 antagonists in the treatment of cognition deficit disorders
CA1327163C (en) Anxiolytically active piperazine derivatives
JP2002326934A (ja) ピロール誘導体を使用するための方法、キット及び組成物
JPWO2005007191A1 (ja) 医薬組成物
CA2357110A1 (en) Method for the treatment of polycystic kidney disease
WO1995003041A1 (en) Method of inhibiting the production of human immunodeficiency viruses with substituted azaspiranes
WO1995028933A1 (en) Use of arylpiperazine derivatives for the treatment of parkinson's disease and psychosis
JPH09500648A (ja) 置換アザスピランによるヒト免疫不全ウイルス複製の阻害法
EP0717622A1 (en) Methods of treating hiv with azaspiranes
WO1993014760A2 (en) Methods
NZ222401A (en) Pharmaceutical compositions which include a calcium antagonist and 7-(n-(1(s)-ethoxycarbonyl-3-phenylpropyl)-(s)-alanyl)-1,4-dithia-7-azaspiro(4,4)nonane-8-(s)-carboxylic acid